Modified de Gramont with oxaliplatin for advanced colorectal cancer
Author Information
Author(s): Braun M S, Adab F, Bradley C, McAdam K, Thomas G, Wadd N J, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders M P, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards F J, Seymour M T
Primary Institution: Cancer Research UK Centre in Leeds
Hypothesis
Can the OxMdG regimen improve treatment outcomes for patients with advanced colorectal cancer?
Conclusion
The OxMdG regimen is well-tolerated and shows promising efficacy as a first-line treatment for advanced colorectal cancer.
Supporting Evidence
- 52 patients had measurable disease at the outset.
- Overall response rate was 53%, with 8.1% achieving complete response.
- Median time to progression was 8.3 months.
- Median overall survival was 14.5 months.
- 62% of patients were alive one year after registration.
Takeaway
This study tested a new cancer treatment that combines two drugs and found it works well and is easy for patients to handle.
Methodology
A prospective multicentre phase 2 study involving 56 patients with inoperable metastatic colorectal cancer, treated with the OxMdG regimen.
Potential Biases
Potential bias due to the lack of randomization and reliance on self-reported outcomes.
Limitations
The study was limited to a single-arm design without a control group.
Participant Demographics
Patients included 38 males and 17 females, with a median age of 59 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website